CD4+/CD56+ Hematodermic Neoplasm Presenting in the Skin: A Tunisian Case Report and Current Review of the Literature


The CD4+/CD56+ hematodermic neoplasm is a rare aggressive systemic neoplasm for which effective therapies have not yet been established, it is clinically characterized by cutaneous involvement with spread to bone marrow, blood and poor prognosis with current chemotherapy regimens. Our objective is to report diagnosis and treatment difficulties of CD4+/CD56+ hematodermic neoplasm. We describe here a Tunisian man who presented with subcutaneous ulcerated lesion localized in the right leg and multiples generalized nodules. Skin biopsy showed an atypical lymphoid cell infiltration with an angiocentric pattern and extensive necrosis by immuno-histochemical analysis, these cells were positive for CD4, CD56, granzyme B and negative for CD8, CD123, CD20 and CD30. T-cell rearrangement and Epstein-Barr-virus (EBV) in situ hybridation studies were negative. The patient underwent 5 cycles chemotherapy SMILE regimen monthly sandwiched with radiotherapy on the residual lesions of the right leg with great tolerance but he relapsed within 8months with skin, blood, bone marrow, lung, and cerebrospinal involvement. Based on these findings, the patient was diagnosed with CD4+/CD56+ hematodermic neoplasm (blastic NK-like T-cell lymphoma) treated with one course of hyper-CVAD regimen, he died within 20 days with a septic chok. Despite the use of L-Asparaginase and radiotherapy the prognosis is very poor; we suggest the exploration for highly active drugs, hematopoietic stem cell transplantation (HSCT) is crucial to improve survival.

Share and Cite:

Youssef, Y. , Sayed, N. , Zahra, K. , Gmidène, A. , Salah, N. , Abdelkader, A. , Brahem, N. , Sennana, H. , Belajouza, C. and Khelif, A. (2012) CD4+/CD56+ Hematodermic Neoplasm Presenting in the Skin: A Tunisian Case Report and Current Review of the Literature. Open Journal of Blood Diseases, 2, 95-99. doi: 10.4236/ojbd.2012.24018.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] R. Dummer, K. Asagoe, A. Cozzio, G. Burg, U. Doebbeling and P. Golling, “Recent Advances in Cutaneous Lymphomas,” Journal of Dermatological Science, Vol. 48, No. 3, 2007, pp. 157-167. HUdoi:10.1016/j.jdermsci.2007.09.001U
[2] C. M. Magro, P. Porcu, J. S. Schaefer, J. W. Erter, R. R. Furman and P. K. Shitabata et al., “Cutaneous CD4+ CD56+ Hematologic Malignancies,” Journal of the American Academy Dermatology, Vol. 63, No. 2, 2010, pp. 292-308. HUdoi:10.1016/j.jaad.2009.08.044U
[3] R. G. Asher and K. Hollowood, “Primary Cutaneous Lymphoma: An Overview Based on the WHO-EORTC Classification, Mini-Symposium: Haematopathology Update III,” Diagnostic Histopathology, Vol. 16, No. 4, 2010, pp. 168-181.
[4] K. K. Sra, J. W. Labiche, R. Rapini, R. Jordon, S. Raimer and S. Tyring, “T/Natural Killer-Cell Lymphomas,” Journal of the American Academy Dermatology Letters, 2005, pp. 708-709.
[5] M. W. Bekkenk, P. M. Jansen, C. J. L. M. Meijer and R. Willemze, “CD56+ Hematological Neoplasms Presenting in the Skin: A Retrospective Analysis of 23 New Cases and 130 Cases from the Literature,” Annals of Oncology, Vol. 15, No. 7, 2004, pp. 1097-1108. HUdoi:10.1093/annonc/mdh268U
[6] Y. L. Kwong, “Natural Killer-Cell Malignancies: Diagnosis and Treatment,” Leukemia, Vol. 19, No. 12, 2005, pp. 2186-2194. HUdoi:10.1038/sj.leu.2403955U
[7] M. Shapiro, M. A. Wasik, J. M. Junkins-Hopkins, A. H. Rook, C. C. Vittorio and H. Ikatura et al., “Complete Remission in Advanced Blastic NK-Cell Lymphoma/ Leukemia in Elderly Patients Using the Hyper-CVAD Regimen,” American Journal of Hematology, Vol. 74, No. 1, 2003, pp. 46-51. HUdoi:10.1002/ajh.10381UH
[8] J. W. Tjiu and C. H. Hsiao, “Blastic Natural Killer-Cell Lymphoma Presenting in the Skin,” Tzu Chi Medical Journal, Vol. 19, No. 3, 2007, pp. 173-178.
[9] R. P. Falcao, A. B. Garcia, M. G. Marques, B. P. Simoes, B. A. Fonseca and M. L. Rodrigues, et al., “Blastic CD4 NK Cell Leukemia/Lymphoma: A Distinct Clinical Entity,” Leukemia Research, Vol. 26, No. 9, 2002, pp. 803-807.
[10] R. Suzuki and S. Nakamura, “Malignancies of Natural Killer (NK) Cell Precursor: Myeloid/NK Cell Precursor Acute Leukemia and Blastic NK Cell Lymphoma/ Leukemia,” Leukemia Research, Vol. 23, No. 7, 1999, pp. 615-624.
[11] J. V. E. Reyes, T. Al-Saleem, V. G. Robu and M. R. Smith, “Extranodal NK/T-cell Lymphoma Nasal Type: Efficacy of Pegaspargase. Report of Two Patients from the United States and Review of Literature,” Leukemia Research, Vol. 34, No. 1, 2010, pp. 50-54. HUdoi:10.1016/j.leukres.2009.09.002U
[12] M. Yamaguchi, R. Suzuki, Y. L. Kwong, W. S. Kim, Y. Hasegawa and J. Izutsu Kiya, et al., “Phase I Study of Dexamethasone, Methotrexate, Ifosfamide, L-Asparaginase and Etoposide (SMILE) Chemotherapy for Advanced-Stage, Relapsed or Refractory Extranodal Natural Killer (NK)/T-cell Lymphoma and Leukemia,” Cancer Science, Vol. 99, No. 5, 2008, pp. 1016-1020. HUdoi:10.1111/j.1349-7006.2008.00768.xU
[13] P. Ng Ashley, L. Stephen, R. Timothy, Mc. Cormack, C. Prince and H. M. D. Awesterman, “Primary Cutaneous CD4+/CD56+ Hematodermic Neoplasm (Blastic NK-Cell Lymphoma): A Report of Five Cases,” Hematologica, Vol. 91, No. 1, 2008, pp. 143-144.
[14] J. J. Leitenberger, C. N. Berthelot, K. D. Polder, P. McLaughlin, D. Jones and M. Duvic, “CD4+ CD56+ Hematodermic/Plasmacytoid Dendritic Cell Tumor with Response to Pralatrexate,” Journal of the American Academy Dermatology, Vol. 58, No. 3, 2008, pp. 480-484. Udoi:10.1016./jaad.2004
[15] E. C. Parlette, Z. Elliott, F. W. Hall and B. S. Grabam, “Primary Cutaneous Blastic Natural Killer Cell Lymphoma,” Journal of the American Academy Dermatology, Vol. 53, No. 4, 2005, pp. 742-743.

Copyright © 2024 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.